HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Future OTC Technologies Will Bring Regulatory Challenges – Gottlieb

This article was originally published in The Tan Sheet

Executive Summary

Technological changes in the OTC drug marketplace will prompt changes in the approval process for nonprescription products, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD

You may also be interested in...

Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb

Drug sponsors should work with insurers in advance of nonprescription switches to develop reimbursement plans to benefit consumers, particularly when considering a behind-the-counter switch, former FDA Deputy Commissioner Scott Gottlieb advises

Deputy commissioner leaving FDA

Scott Gottlieb, MD, the agency's Medical & Scientific Affairs exec, announces Dec. 12 he will leave to return to the American Enterprise Institute think tank, where he was a resident fellow before joining FDA 18 months ago. He has worked on FDA policy initiatives, including improving the advisory committee process and improving the effectiveness of the agency's approaches to communicating risk information to the public. Gottlieb, who practiced internal medicine during his tenure as a public official, also helped facilitate implementing new regulations and policies, including drug and biologic products labeling and expanded access to drugs under development. Gottlieb, who is leaving FDA effective Jan. 16, 2007, commented this year that technological changes in the drug marketplace will prompt changes in the approval process for nonprescription products and will lead to opportunities for development of new OTCs, particularly for chronic conditions (1"The Tan Sheet" May 8, 2006, p. 4)...

SPL for OTCs

The Center for Drug Evaluation & Research will focus on structured product labeling (SPL) requirements for OTC drugs once it gets past the initial launch of SPL for Rx drugs in late October, CDER Office of Business Project Support Program Manager Lisa Stockbridge stated. Starting Oct. 31, manufacturers must submit label changes in electronic format using structured product labeling for all NDAs and ANDAs. Focus on SPL for OTCs is targeted for August 2006, she said during the Regulatory Affairs Professional Society annual meeting in Baltimore, Md., Oct. 17. Transition to SPL has been delayed several times since FDA's release of draft guidance on the topic in February 2004; the final guidance was issued in April. Implementing SPL places a "larger workload" on CDER, with the biggest burden on generic drugs due to a higher volume of labeling, Stockbridge said. The FDAer urged patience as the agency begins to adapt to the new system...

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts